Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06354322

Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis

Patients with autoinflammatory diseases (AID) have recurrent episodes of systemic inflammation accompanied by nonspecific elevation of blood inflammation markers typically absent between attacks. A complication of autoinflammatory diseases is AA amyloidosis, which can lead to renal failure and dialysis. Advances in genetic analysis have led to the identification of new autoinflammatory diseases and thus new pathophysiological pathways.

However, genetic analyses are sometimes confronted with results that are difficult to interpret. These are the Variants of Unknown Significance, for which genetic analysis alone does not allow to determine if the genetic mutation is responsible for the symptoms.

genetic analysis sometimes has limitations in the diagnosis of AID which can only be overcome by pathophysiological studies of the variants found.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Service médecine interne-Hôpital Tenon

Paris, 75020, France

Location status: Recruiting

About this study

The study aim to explore variants of undetermined significance in major and minor patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity.

National multicenter research: internal medicine department of Tenon Hospital, pediatric department of Versailles Hospital and pediatric dermatology department of Necker Enfants Malades Hospital in Paris

Samples will be collected at the inclusion visit or at subsequent visits of the patient to the department during a blood draw performed as part of routine care by a registered nurse.

The total volume of the sample will be 24 mL per 6 month period maximum, and will not exceed In case of skin involvement of the auto-inflammatory disease, a skin biopsy may be performed as part of the patient's follow-up care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for patients to be studied:

  • Patients over 18 years of age with the capacity to give express free and informed consent and;
  • Minor patients under 18 years of age with both parents or legal guardians giving consent;
  • Patients with unclassified IAD or AA amyloidosis of undetermined etiology;
  • Patients followed in one of the study departments;
  • Patients weighing more than 15 kg.

Inclusion criteria

for control patients:

  • Patients over 18 years of age with the capacity to give free and informed express consent;
  • Patients with IAD classified with well-defined international criteria or ;
  • Patients who have undergone cosmetic surgery or blood donors).

Exclusion criteria

  • Patients unable to give express free and informed consent;
  • Subjects under guardianship, curatorship or safeguard of justice;
  • Subjects who do not speak French;
  • Subjects unable to answer questions or express themselves;
  • Patients weighing less than 15 kg;
  • Patients without social security coverage

Treatment and study plan

Primary outcomes

  1. Exploration of VUS in AutoInflammatory Diseases

    Time frame: Up to 4 years

    To explore variants of undetermined significance (VUS)in patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity.

Secondary outcomes

  1. Pathophysiology of Autoinflammatory Diseases

    Time frame: Up to 4 years

    To improve the knowledge on the pathophysiology of Autoinflammatory Diseases: to determine the role of new inflammation pathways in AutoInflammatory Diseases

  2. Role of other innate immune cells in AutoInflammatory Diseases

    Time frame: Up to 4 years

    Evaluate the role of other innate immune cells (neutrophils, mast cells...) and their mediators

  3. Improve knowledge of AA amyloidosis

    Time frame: Up to 4 years

    Improve knowledge of AA amyloidosis, a complication of autoinflammatory diseases

Study contacts

Contact information is provided by the study sponsor or research team.

Sophie GEORGIN-LAVIALLE, Professor

CONTACT

[email protected]

00 33 1 56 01 72 04

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Physiopathological Investigation of Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis

Acronym: IPHYGENI MAI

Important dates

Study start
2025
Primary completion
2039
Study completion
2039
First posted
Apr 9, 2024
Registry last updated
Sep 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.